Log In
Print
BCIQ
Print
Print this Print this
 

bioerodible latanprost implant (Durasert)

  Manage Alerts
Collapse Summary General Information
Company pSivida Corp.
DescriptionSustained-release, bioerodible implant delivering latanoprost into the subconjunctival space of the eye using pSivida's Durasert technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase I/II
Standard IndicationOcular hypertension
Indication DetailsReduce intraocular pressure in patients with ocular hypertension or glaucoma
Regulatory Designation

Partner

Pfizer Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today